Use of granulocyte macrophage colony stimulating factor in children after orthotopic liver transplantation

Eunice Trindade, Pierre Maton, Raymond Reding, Jean De Ville De Goyet, Jean Bernard Otte, Jean Paul Buts, Etienne M. Sokal

Research output: Contribution to journalArticlepeer-review


Background/Aims: Bacterial infections complicate the course of up to 80% of pediatric liver transplant recipients, and in some cases, neutropenia, surgical complications and/or antibiotic resistance prevent successful control of sepsis. The aim of the present study was to evaluate the safety and efficacy of granulocyte macrophage colony stimulating factors (GM-CSF) in treating neutropenia following pediatric orthotopic liver transplantation. Methods: Among a cohort of 430 pediatric orthotopic liver transplantation recipients, 13 children (12 months to 15 years, median 2 years, 10 males) received 15 courses of GM-CSF, 5 μg · kg-1 · d-1 subcutaneously, during their post-transplant course. In nine cases, the initial neutrophil count was below 1000/ram3. Ten patients were infected. Three received GM- CSF for severe sepsis without neutropenia. The mean duration of treatment was 16.3 days (range 449). Results: In all but one neutropenic patient the neutrophil count increased above 1500/mm3 and the mean neutrophil count increased from 1392±1912/mm3 (range 130-7170, median 640) to 4508±2459/mm3 (range 350-9630, median 4390) (p

Original languageEnglish
Pages (from-to)1054-1057
Number of pages4
JournalJournal of Hepatology
Issue number6
Publication statusPublished - Jun 1998


  • Children
  • Epstein-Barr virus
  • G-CSF
  • GM-CSF
  • Liver transplantation
  • Neutropenia
  • Posttransplant lymphoproliferative disease

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Use of granulocyte macrophage colony stimulating factor in children after orthotopic liver transplantation'. Together they form a unique fingerprint.

Cite this